Skip to content

H2020FP7HORIZON

Astrazeneca AB

Country
SESweden
Defence projects
0
Projects, all programmes
150
As coordinator
8
EU contribution (CORDIS)
EUR 17,186,814
Active
2008 to 2026

Projects

150 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
HaloVerseAdvancing Europe's Next Generations on the Path to Sustainability – Expanding the Universe of Enzymatic Halogenation ChemistryHORIZON2026Associated partnerNot stated
ELEGANCEMachine learning for integrated multi-parametric enzyme and bioprocess designHORIZON2026Associated partnerNot stated
ON-TRACTOligoNucleotide Technologies for Rapid Advancement of Cancer TherapiesHORIZON2026Associated partnerNot stated
READIResearch in Europe and Diversity InclusionHORIZON2025ParticipantEUR 0
SciLifeLab PULSESciLifeLab Programme for fUture Leaders in life SciencEHORIZON2025Associated partnerEUR 0
LifeLUNGImproving Life expectancy of LUNG transplant recipients through innovative ex vivo perfusion gene therapyHORIZON2025Associated partnerNot stated
NEXTMARINENovel enzymes from extreme marine environments as a source for value-added targetsHORIZON2025ParticipantNot stated
EFFECTA European Training Program to Foster the Full Therapeutic Potential of Antisense Technology across TissuesHORIZON2025ParticipantEUR 293,710
NAP4DIVENon-Animal Platform for Nanoparticle-Based Delivery across the blood-brain barrier Interface with Vehicle EvolutionHORIZON2025ParticipantEUR 870,910
TargetRNATargeting RNA with small moleculesHORIZON2024ParticipantEUR 293,710
ORGESTRAOrganoid technologies for disease modeling, drug discovery and development for rare diseasesHORIZON2024Associated partnerEUR 0
GRANITEIntegrated AI Diagnostics in Breast CancerHORIZON2024Associated partnerEUR 0
ERDERAEUROPEAN RARE DISEASES RESEARCH ALLIANCEHORIZON2024Associated partnerEUR 0
MeCHaNiSMMechanical Characterisation of Nucleic Acids using Single Molecule MethodsHORIZON2024Associated partnerEUR 0
LIVERAIMA Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized TherapyHORIZON2024ParticipantEUR 0
MC4DDMacrocycles for Drug DiscoveryHORIZON2024ParticipantEUR 293,710
NATPRIMEEffective Delivery of Nucleic Acid Therapeutics via Designed NanocarriersHORIZON2024ParticipantEUR 293,710
CURE HEARTandBRAINCURE HEARTandBRAIN postdoctoral COFUND programme by CNICHORIZON2024Associated partnerEUR 0
Project-COMFORTPatient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)HORIZON2024ParticipantEUR 0
FluoNeeDFluorinated Lipid Nanoparticles for Gene Delivery and DiagnosticsHORIZON2024Associated partnerEUR 0

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.